Analysts Offer Insights on Healthcare Companies: NuVasive (NASDAQ: NUVA), West Pharm (NYSE: WST) and Bioverativ Inc (NASDAQ: BIVV)

By Ryan Adsit

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NuVasive (NASDAQ: NUVA), West Pharm (NYSE: WST) and Bioverativ Inc (NASDAQ: BIVV).

NuVasive (NASDAQ: NUVA)

Jefferies analyst Raj Denhoy reiterated a Buy rating on NuVasive (NASDAQ: NUVA) yesterday and set a price target of $84. The company’s shares closed yesterday at $77.38, close to its 52-week high of $81.06.

According to TipRanks.com, Denhoy is a top 100 analyst with an average return of 17.7% and a 76.1% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Varian Medical Systems, and Zimmer Biomet Holdings.

Currently, the analyst consensus on NuVasive is Strong Buy and the average price target is $85.71, representing a 10.8% upside.

In a report issued on June 28, Cowen & Co. also reiterated a Buy rating on the stock with a $90 price target.
West Pharm (NYSE: WST)

Jefferies analyst David Windley reiterated a Hold rating on West Pharm (NYSE: WST) yesterday and set a price target of $100. The company’s shares closed yesterday at $94.42.

According to TipRanks.com, Windley is a top 25 analyst with an average return of 19.4% and a 79.8% success rate. Windley covers the Services sector, focusing on stocks such as Quintiles Transnational, Quest Diagnostics Inc, and WellCare Health Plans.

West Pharm has an analyst consensus of Hold, with a price target consensus of $100.

Bioverativ Inc (NASDAQ: BIVV)

In a report released yesterday, Eun Yang from Jefferies reiterated a Buy rating on Bioverativ Inc (NASDAQ: BIVV), with a price target of $67. The company’s shares closed yesterday at $60.29, close to its 52-week high of $63.23.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 4.0% and a 50.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Bioverativ Inc is Moderate Buy and the average price target is $57.33, representing a -4.9% downside.

In a report issued on June 26, Stifel Nicolaus also reiterated a Buy rating on the stock with a $62 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.